logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11554106 B1

PDFFull Text
Date of Patent:
Jan. 17, 2023

Filed:

Mar. 07, 2018

Prevention of the risks associated with drug-induced qt interval prolongation by using a specific inhibitor of the production of ros of miochondrial origin

Applicants:

Marc Childs, Paris, FR;

Jacque Sauzieres, Dampierre en Yvelines, FR;

Olivier Petitjean, Senlis, FR;

Guillaume Petitjean, Paris, FR;

Elodie Petitjean, Senlis, FR;

Grégoire Petitjean, Verrieres le Buisson, FR;

Inventors:

Olivier Petitjean, Senlis, FR;

Guillaume Petitjean, Paris, FR;

Elodie Petitjean, Senlis, FR;

Grégoire Petitjean, Verrieres le Buisson, FR;

Assignee:

Other;

Attorney:

TraskBritt

Primary Examiner:

Alicia L Otton

Int. Cl.
CPC ...
A61K 31/385 (2006.01); A61K 47/55 (2017.01); A61P 9/06 (2006.01); A61K 31/222 (2006.01); A61K 31/4439 (2006.01); A61K 31/445 (2006.01); A61K 31/4468 (2006.01); A61K 31/454 (2006.01); A61K 31/4709 (2006.01); A61K 31/496 (2006.01); A61K 31/5383 (2006.01); A61K 31/5415 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/385 (2013.01); A61K 31/222 (2013.01); A61K 31/445 (2013.01); A61K 31/4439 (2013.01); A61K 31/4468 (2013.01); A61K 31/454 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); A61K 31/5383 (2013.01); A61K 31/5415 (2013.01); A61K 45/06 (2013.01); A61K 47/55 (2017.08); A61P 9/06 (2018.01);
Abstract

A method of treating a subject for reducing the risk of QT space prolongation associated with the intake of a drug known to prolong QT space includes administering to the subject at least one specific inhibitor of mitochondrial ROS production selected from among anethole trithione (ATT), 4-OH-anethole trithione (ATX), and an ATX ester, and administering to the subject the drug known to prolong QT space.

Find Patent Forward Citations

Petitjean, Olivier. (2023). Prevention of the risks associated with drug-induced qt interval prolongation by using a specific inhibitor of the production of ros of miochondrial origin (U.S. Patent No. 11554106). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11554106

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…